RVL Pharmaceuticals plc to Discuss Fourth Quarter and Full 15-03-2023, 17:56

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai 18-09-2024, 22:07

Solar Integrated Roofing Corp. to Participate in the 35th 10-03-2023, 20:34